Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

NCT04676087 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Lack of funding

Conditions

Mycosis Fungoides
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Sezary Syndrome

Interventions

PROCEDURE: Extracorporeal Photopheresis
BIOLOGICAL: Mogamulizumab
OTHER: Quality-of-Life Assessment

Sponsor

Emory University

Collaborators

[object Object]